• Cancer investigation · Jun 2013

    Multicenter Study

    Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.

    • John D Hainsworth, David M Waterhouse, William C Penley, Dianna L Shipley, Dana S Thompson, Charles D Webb, and F Anthony Greco.
    • Sarah Cannon Research Institute, Nashville, TN 37203, USA. jhainsworth@tnonc.com
    • Cancer Invest. 2013 Jun 1; 31 (5): 323-9.

    PurposeTo evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC).MethodsPatients with advanced RCC and ≤ 1 previous targeted therapy were treated.ResultsMaximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common.ConclusionsFifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…